SCHEMBL3425538

SCHEMBL3425538

Cc1ccc(-c2nc(C)cc(Cl)n2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.72
KMT2A Q03164 4/20 0.50
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
MEN1 O00255 3/20 0.46
GBA1 P04062 1/20 0.46
PTGS2 P35354 1/20 0.45
NR1H4 Q96RI1 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
HSP90AA1 P07900 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTT P42858 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7375735 0.90 LMNA (0.57) LMNAKMT2ANPC1RAB9AMEN1
SCHEMBL11169691 0.85 NPC1 (0.53) LMNAKMT2ANPC1RAB9AMEN1
SCHEMBL9013500 0.85 LMNA (0.68) LMNAKMT2ANPC1RAB9AMEN1
SCHEMBL1772953 0.84 LMNA (1.00) LMNAKMT2ANPC1RAB9AMEN1
SCHEMBL17412398 0.84 MEN1 (0.55) LMNAKMT2AMEN1PTGS2NR1H4
SCHEMBL11513769 0.82 LMNA (0.70) LMNAKMT2ANPC1RAB9AMEN1
SCHEMBL28330431 0.82 LMNA (0.64) LMNAKMT2ANPC1RAB9AALDH1A1
SCHEMBL632828 0.82 LMNA (0.64) LMNAKMT2ANPC1RAB9AMEN1
SCHEMBL8031410 0.80 LMNA (0.62) LMNAKMT2ANPC1RAB9AMAPT
SCHEMBL5487045 0.79 LMNA (0.71) LMNAKMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7731985-B2 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces CIBA SPECIALTY CHEMICALS CORPORATION (US) 2010-06-08 US disclosed
EP-1484971-B1 USE OF 4-AMINOPYRIMIDINES FOR THE ANTIMICROBIAL TREATMENT OF SURFACES CIBA SC HOLDING AG (CH) 2007-07-04 EP disclosed
US-20050143387-A1 4-Aminopyrimidines and their use for the antimicrobial treatment of surfaces CIBA SPECIALTY CHEMICALS CORP. 2005-06-30 US disclosed
EP-1484971-A1 4-AMINOPYRIMIDINES AND THEIR USE FOR THE ANTIMICROBIAL TREATMENT OF SURFACES Ciba SC Holding AG (CH) 2004-12-15 EP disclosed
WO-2003077656-A1 4-AMINOPYRIMIDINES AND THEIR USE FOR THE ANTIMICROBIAL TREATMENT OF SURFACES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-09-25 WO disclosed
EP-0031796-B1 4-HETEROCYCLYL-4'-VINYL-STILBENES CIBA-GEIGY AG (CH) 1985-01-23 EP disclosed
EP-0020298-B1 BENZOXAZOLYL STILBENES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS OPTICAL BRIGHTENERS FOR ORGANIC MATERIALS CIBA-GEIGY AG (CH) 1983-06-22 EP disclosed
US-4366189-A WHITENERS CIBA-GEIGY CORPORATION (US) 1982-12-28 US disclosed
US-4297234-A OPTICAL BRIGHTENERS CIBA-GEIGY CORPORATION (US) 1981-10-27 US disclosed
EP-0031796-A2 4-Heterocyclyl-4'-vinyl-stilbenes CIBA-GEIGY AG (CH) 1981-07-08 EP disclosed
EP-0020298-A1 Benzoxazolyl stilbenes, process for their preparation and their use as optical brighteners for organic materials CIBA-GEIGY AG (CH) 1980-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143387-A1 4-Aminopyrimidines and their use for the antimicrobial treatment of surfaces DPM1, UNG, DPYD LMNA 4211/4885KMT2A 3109/4885NPC1 4111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.